206 related articles for article (PubMed ID: 38152697)
21. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA
J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
24. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
25. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Chang C; Li X; Cheng K; Cai Z; Xiong J; Lv W; Li R; Zhang P; Cao D
Oncologist; 2023 Jul; 28(7):e575-e584. PubMed ID: 35930304
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
[TBL] [Abstract][Full Text] [Related]
27. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.
Chow LW; Xu B; Gupta S; Freyman A; Zhao Y; Abbas R; Vo Van ML; Bondarenko I
Br J Cancer; 2013 May; 108(10):1985-93. PubMed ID: 23632474
[TBL] [Abstract][Full Text] [Related]
28. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
29. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Vinayak S; Tolaney SM; Schwartzberg L; Mita M; McCann G; Tan AR; Wahner-Hendrickson AE; Forero A; Anders C; Wulf GM; Dillon P; Lynce F; Zarwan C; Erban JK; Zhou Y; Buerstatte N; Graham JR; Arora S; Dezube BJ; Telli ML
JAMA Oncol; 2019 Aug; 5(8):1132-1140. PubMed ID: 31194225
[TBL] [Abstract][Full Text] [Related]
30. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
31. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
Moore KN; Hong DS; Patel MR; Pant S; Ulahannan SV; Jones S; Meric-Bernstam F; Wang JS; Aljumaily R; Hamilton EP; Wittchen ES; Wang X; Lin AB; Bendell JC
Target Oncol; 2021 Sep; 16(5):569-589. PubMed ID: 34559360
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
34. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Kong A; Rea D; Ahmed S; Beck JT; López López R; Biganzoli L; Armstrong AC; Aglietta M; Alba E; Campone M; Hsu Schmitz SF; Lefebvre C; Akimov M; Lee SC
Oncotarget; 2016 Jun; 7(25):37680-37692. PubMed ID: 27129177
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Lynce F; Williams JT; Regan MM; Bunnell CA; Freedman RA; Tolaney SM; Chen WY; Mayer EL; Partridge AH; Winer EP; Overmoyer B
Cancer Chemother Pharmacol; 2021 May; 87(5):673-679. PubMed ID: 33585999
[TBL] [Abstract][Full Text] [Related]
36. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
38. Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y; Yost SE; Cui Y; Ruel C; Murga M; Tang A; Martinez N; Schmolze D; Waisman J; Patel N; Vora L; Tumyan L; Bozoghlanian M; Stewart D; Frankel PH
Oncologist; 2023 Jul; 28(7):e498-e507. PubMed ID: 37023705
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
Yonemori K; Shimomura A; Yasojima H; Masuda N; Aogi K; Takahashi M; Naito Y; Shimizu S; Nakamura R; Hashimoto J; Yamamoto H; Hirakawa A; Michimae H; Hamada A; Yoshida T; Sukigara T; Tamura K; Fujiwara Y
Eur J Cancer; 2019 Mar; 109():84-91. PubMed ID: 30703739
[TBL] [Abstract][Full Text] [Related]
40. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
